AbbVie (ABBV) Tops Q2 EPS by 4c, Raises FY Guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.87 billion versus the consensus estimate of $13.51 billion.

GUIDANCE:

AbbVie sees FY2023 EPS of $10.90-$11.10, versus the consensus of $10.85.

• Raises 2023 Adjusted Diluted EPS Guidance Range from $10.57 - $10.97 to $10.90 - $11.10, which Includes an Unfavorable Impact of $0.23 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2023

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FirstCash to acquire UK pawn operator Ramsdens for £206 million
• AbbVie sharpens immunology focus with $10.9 billion Apogee deal